These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 6804681)

  • 41. Relative potency of mexiletine, lidocaine, and tocainide as inhibitors of rat liver CYP1A1 activity.
    Wei X; Loi CM; Jarvi EJ; Vestal RE
    Drug Metab Dispos; 1995 Dec; 23(12):1335-8. PubMed ID: 8689940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hemodynamic repercussions and clinical tolerance of 6 class I anti-arrhythmia agents in acute myocardial infarction].
    Bernard R; Renard M; Shita A; de Hemptinne J; Gillet JM; Lewinson H; Liebens I; Waterschoot P
    Ann Cardiol Angeiol (Paris); 1986 Apr; 35(4):195-8. PubMed ID: 3090925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical pharmacology of anti-arrhythmia agents].
    Zeng GY
    Zhonghua Xin Xue Guan Bing Za Zhi; 1983 Mar; 11(1):15-9. PubMed ID: 6884198
    [No Abstract]   [Full Text] [Related]  

  • 44. [Perspectives in anti-arrhythmia pharmacological therapy].
    Furlanello F; Vergara G; Inama G; Dal Forno P; Bettini R; Disertori M
    Cardiologia; 1984; 29(1-2):73-84. PubMed ID: 6442869
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure.
    MacMahon B; Bakshi M; Branagan P; Kelly JG; Walsh MJ
    Br J Clin Pharmacol; 1985 Apr; 19(4):429-34. PubMed ID: 3922392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ventricular arrhythmias. An assessment of newer therapeutic agents.
    Skluth H; Grauer K; Gums J
    Postgrad Med; 1989 May; 85(6):137-8, 141-8, 153. PubMed ID: 2496401
    [No Abstract]   [Full Text] [Related]  

  • 47. New antiarrhythmic agents.
    Pepper GA
    Nurse Pract; 1986 Jul; 11(7):62-4, 67, 70. PubMed ID: 3737022
    [No Abstract]   [Full Text] [Related]  

  • 48. Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents.
    Roden DM
    Postgrad Med; 1985 Sep; 78(4):28-37. PubMed ID: 2412217
    [No Abstract]   [Full Text] [Related]  

  • 49. On the kinetics and dynamics of tocainide and its metabolites.
    Ronfeld RA; Wolshin EM; Block AJ
    Clin Pharmacol Ther; 1982 Mar; 31(3):384-92. PubMed ID: 6800678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tocainide plus quinidine for treatment of ventricular arrhythmias.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Am J Cardiol; 1988 Mar; 61(8):570-3. PubMed ID: 3125737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mexiletine in clinical practice.
    Boyle DM
    Acta Cardiol Suppl; 1980; (25):137-45. PubMed ID: 6990665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.
    Thomson AH; Murdoch G; Pottage A; Kelman AW; Whiting B; Hillis WS
    Br J Clin Pharmacol; 1986 Feb; 21(2):149-54. PubMed ID: 3082345
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New antiarrhythmic agents: mexiletine, tocainide, encainide, flecainide, and amiodarone.
    Morganroth J
    Ration Drug Ther; 1987 Apr; 21(4):1-6. PubMed ID: 3685373
    [No Abstract]   [Full Text] [Related]  

  • 54. Breast milk tocainide levels.
    Wilson JH
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):497. PubMed ID: 2465453
    [No Abstract]   [Full Text] [Related]  

  • 55. Antiarrhythmic effects of tocainide and lidocaine in dogs.
    Aberg G; Ronfeld R; Aberg L; Fitzgerald T; McCollom K; Moller R
    Acta Pharmacol Toxicol (Copenh); 1983 Aug; 53(2):146-52. PubMed ID: 6414246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine.
    Duff HJ; Roden DM; Marney S; Colley DG; Maffucci R; Primm RK; Oates JA; Woosley RL
    Am Heart J; 1984 Mar; 107(3):585-9. PubMed ID: 6421133
    [No Abstract]   [Full Text] [Related]  

  • 57. Depressant effects of drugs used in myotonia therapy.
    Courtney KR
    Proc West Pharmacol Soc; 1982; 25():159-61. PubMed ID: 6289335
    [No Abstract]   [Full Text] [Related]  

  • 58. Pulmonary fibrosis associated with tocainide: report of a case with literature review.
    Feinberg L; Travis WD; Ferrans V; Sato N; Bernton HF
    Am Rev Respir Dis; 1990 Feb; 141(2):505-8. PubMed ID: 2137316
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unexpected mexiletine responses of a mutant cardiac Na+ channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access.
    Sasaki K; Makita N; Sunami A; Sakurada H; Shirai N; Yokoi H; Kimura A; Tohse N; Hiraoka M; Kitabatake A
    Mol Pharmacol; 2004 Aug; 66(2):330-6. PubMed ID: 15266024
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Action of tocainide and mexiletine on the excitation threshold of myelinated nerves.
    Tippe A; Linderer EM
    Eur J Pharmacol; 1987 Sep; 141(2):225-33. PubMed ID: 3119354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.